|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
specialized healthcare professionals
|
|
gptkbp:antigen
|
gptkb:CD19
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2021
|
|
gptkbp:ATCCode
|
L01XL10
|
|
gptkbp:blackBoxWarning
|
cytokine release syndrome
neurological toxicities
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Juno_Therapeutics
gptkb:Bristol_Myers_Squibb
|
|
gptkbp:drugClass
|
gene therapy
|
|
gptkbp:form
|
cell suspension
|
|
gptkbp:genericName
|
gptkb:lisocabtagene_maraleucel
|
|
gptkbp:hasBoxedWarning
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Breyanzi
|
|
gptkbp:indication
|
gptkb:large_B-cell_lymphoma
relapsed or refractory diffuse large B-cell lymphoma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
genetically modified autologous T cells targeting CD19
|
|
gptkbp:orphanDrugStatus
|
yes
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:requiresHospitalization
|
yes
|
|
gptkbp:requiresPreconditioning
|
yes
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:source
|
autologous T cells
|
|
gptkbp:storage
|
-150°C or below
|
|
gptkbp:bfsParent
|
gptkb:gene_therapy
|
|
gptkbp:bfsLayer
|
5
|